The Burden of Lung Cancer

Despite the use of aggressive surgery and combination chemotherapy, lung cancer remains difficult to control and is the biggest killer among cancers at 154,000 annual US deaths.

Lung cancer kills more people per year than prostate, pancreas, breast, and colon cancers combined.

Standard of Care

The pharmaceutical standard of care for lung cancer is primarily intravenous chemotherapy drugs, which have limited efficacy because of low drug concentration delivered to the lungs due to blood volume dilution.

Targeted Therapy

Quench Medical’s inhalation technology delivers the drug directly to tumor tissues in the lung thereby enhancing its efficacy due to increased local drug concentration in the lung, and decreased systemic toxicity due to decreased systemic drug levels in the circulation.

Increased Efficacy and Safety with Lower Doses

Our new method delivers the chemotherapeutic drug via dry powder inhalation to reach lung tumors directly, in lower doses, in order to maximize the effectiveness and safety of the cancer treatment.

Meet the Team

...

Bryce Beverlin II, Ph.D.

Founder & CEO

Linked In

Bryce Beverlin II founded Quench Medical to solve crucial problems in respiratory drug delivery for treating lung diseases. He is driven by a passion to help patients with lung diseases by developing the next-generation of highly performing treatments. Bryce is a physicist entrepreneur with 12 years of R&D experience, postdoctoral commercialization training at the Medical Devices Center, and a physics Ph.D. in a biomedical engineering lab at the University of Minnesota (UMN) who has also developed technologies for Boston Scientific, Teijin Pharma, and the UMN.

...

Nancy Ness

Acting CFO

Linked In

Nancy Ness is a financial professional with extensive experience in biomedical company development who is an expert in shaping rounds of financing in addition to controllership and treasury duties. She has provided key financial and fundraising skills to over 40 early stage and commercial companies in Minnesota, Australia, Ireland, Pennsylvania, and California. Nancy has also served in various financial positions over the past 35 years, and for 20 years she has been focusing solely on consulting for the medical device and bio-pharma markets.

...

Peter Crosby

Board of Directors

Linked In

Peter Crosby has been Chief Executive Officer or Chairman of 7 medical device companies in four countries. Peter is a specialist at bringing new medical devices to the global market, from concept to profitability. He has served as a key consultant in the fields of business strategy, intellectual property, research and development, capital markets, product launch and market development. Mr. Crosby’s specialties include: medical business development, financing & venture capital, mergers and acquisitions, product development, intellectual property, organizational development, marketing and sales. He has also served as expert witness in several lawsuits on IP, product liability, and commercialization.

...

John Foster

Board of Directors

Linked In

John Foster has more than 30 years of executive management experience and proven expertise in developing and bringing specialty pharmaceuticals and drug-device combination products to market. Mr. Foster is currently CEO of NeuroBridge Therapeutics. He was previously the founder and CEO of CNS Therapeutics, a specialty pharmaceutical company focused on developing and marketing intrathecal drugs for neurological disorders and pain. CNS was sold to Covidien/Mallinckrodt (October 2012). John also serves as Chairman of Gillette Children's Hospital Specialty Healthcare.

Pipeline

Quench Medical's aerosol platform technology is designed to deliver medicine into deep areas of the lung with unprecedented efficiency to greatly increase efficacy in treating pulmonary airway diseases.

Lung Cancer

Directly targeting lung tumors with inhaled chemotherapy to increase efficacy while minimizing systemic toxicity

Asthma

Highly efficient delivery of corticosteroid medications to the undertreated small airways to reduce inflammation

Cystic Fibrosis

Deep penetration of antibiotic therapies to treat infections with high efficiency

News

August 2018

  • Quench Medical joins the Medical Alley Association, a hub of healthcare innovation and resources, right here in Minnesota. Dr. Beverlin is featured and answers questions on their news blog. Read more here.

 

July 2018

  • Quench Medical's CEO Bryce Beverlin II has been invited to participate in the National Heart Lung and Blood Institute's Mentorship Program to connect Dr. Beverlin with veteran CEOs in the greater NHLBI community.

 

June 2018

  • Nancy Ness has joined Quench Medical as acting CFO! We are very excited to have Nancy's experience on board.

  • Quench Medical is featured in MHTA's entrepreneur profile news. Read more here.

 

May 2018

  • Dr. Beverlin presents Quench Medical's progress at the gBETA Medtech's event liveBETA, a celebration of gBETA Medtech's latest class of innovative startups focused on medical technology. 

 

April 2018

  • Quench Medical joins the inaugural cohort of gBETA Medtech accelerator, sponsored by Boston Scientific, Mayo Clinic, and the University of Minnesota. gBETA is a free, seven-week accelerator for early-stage companies with local roots, started by nationally ranked startup accelerator gener8tor. Read more at the Star Tribune

  • Dr. Beverlin attended the Respiratory Drug Delivery conference, sponsored by the VCU School of Pharmacy, where he met with key people in aerosol medicine development in academia, industry, and the FDA.

 

March 2018

  • A $225k SBIR seed grant from the National Institutes of Health is awarded to Quench Medical to develop a novel highly efficient dry powder aerosol formulation.

Contact

Subscribe to our mailing list

* indicates required

Email Us